Precision prescribing of SGLT2-inhibitors in people with type 2 diabetes for primary prevention of heart failure: model development and validation study

It is established that individualised targeting of SGLT2i initiation using SABRE could more efficiently reduce heart failure outcomes compared to current treatment recommendations for those with T2D without ASCVD/HF/CKD.